10-Q: Interpace Biosciences Reports Q2 2026 Results, Focuses on Thyroid Tests

Interpace Biosciences, Inc. filed its Q2 2026 Form 10-Q, detailing a revenue decrease but improved gross profit and operating income compared to the prior year, driven by a strategic shift following the loss of PancraGEN reimbursement.

Summary

• Interpace Biosciences reported Q2 2026 results, showing a slight decrease in revenue to $9.1 million from $9.2 million in Q2 2025, primarily due to the discontinuation of the PancraGEN test.
• Gross profit increased to $5.7 million from $5.3 million, with a gross profit margin of 61.9% compared to 57.1% in the prior year's quarter.
• Operating income from continuing operations turned positive at $0.3 million, an improvement from an operating loss of $0.5 million in Q2 2025.
• For the first six months of 2026, revenue was $18.2 million, down from $20.7 million in the same period of 2025, while net income was $0.9 million, slightly down from $1.0 million.
• The company had $2.7 million in cash and cash equivalents as of June 30, 2026, and anticipates these funds will be sufficient for the next twelve months.
• The company is focusing on its thyroid cancer diagnostic tests, ThyGeNEXT and ThyraMIRv2, and is developing a new pancreatic cancer test, pending CMS reimbursement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive sentiment, reflecting a stabilization after significant operational changes, though future capital needs and market conditions present ongoing challenges.

Positives

• Gross profit margin improved to 61.9% in Q2 2026 from 57.1% in Q2 2025, indicating better cost management relative to revenue.
• Operating income from continuing operations shifted from a loss of $0.5 million in Q2 2025 to a gain of $0.3 million in Q2 2026.
• Cost of revenue as a percentage of revenue decreased to 38.1% in Q2 2026 from 42.9% in Q2 2025, driven by lower variable costs.
• Sales and marketing expenses decreased as a percentage of revenue to 24.2% in Q2 2026 from 31.5% in Q2 2025, partly due to the absence of severance costs.
• The company generated positive cash flow from operations of $0.4 million for the six months ended June 30, 2026.
• Management anticipates current cash and cash equivalents will be sufficient to meet anticipated cash requirements through the next twelve months.

Negatives

• Revenue for Q2 2026 decreased by 1% to $9.1 million compared to $9.2 million in Q2 2025, primarily due to the loss of PancraGEN reimbursement.
• Revenue for the six months ended June 30, 2026 decreased by 12% to $18.2 million compared to $20.7 million in the same period of 2025.
• The company's ability to raise additional capital has been adversely impacted by the delisting of its common stock from Nasdaq.
• The company is still seeking an uplisting to Nasdaq, with no assurance of success.
• The development of a new pancreatic cancer test is subject to significant uncertainties and requires positive CMS reimbursement determination, which is not guaranteed.

Risks

• Reliance on Medicare reimbursement for clinical services and the ability to maintain profitability after CMS ceased reimbursement for the PancraGEN test.
• Dependence on sales and reimbursements from clinical services for all revenue.
• Reliance on sales of molecular diagnostic tests for thyroid cancer (ThyGeNEXT and ThyraMIRv2) following the discontinuance of PancraGEN.
• Ability to generate sufficient revenue from current and future products and solutions to meet financial targets.
• Ability to finance the business on acceptable terms, which may limit growth and development.
• Dependence on third parties for the supply of materials used in clinical tests.
• Potential adverse impact of evolving U.S. regulatory environment for laboratory-developed tests (LDTs), pricing, and patient access limitations.
• Reliance on sales and marketing activities for future growth and expansion.

Future Outlook

The company anticipates that current cash and cash equivalents and forecasted cash receipts will be sufficient to meet its anticipated cash requirements through the next twelve months. Management is exploring various strategic alternatives and financing options to provide additional liquidity. The company is seeking an uplisting of its Common Stock to Nasdaq.

Management Comments

• The Company intends to meet its ongoing capital needs by using its available cash, as well as through targeted margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives.
• The Company continues to explore various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity.
• With the delisting of its common stock, par value $ 0.01 per share (Common Stock), from Nasdaq in February 2021, the Companys ability to raise additional capital on terms acceptable to it has been adversely impacted.
• There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to it.
• The Company is seeking an uplisting of its Common Stock to Nasdaq, but no assurances can be given that a Nasdaq listing will be achieved.

Industry Context

StockSavvy.ai notes that Interpace Biosciences operates in the specialized field of molecular diagnostics, a sector characterized by rapid technological advancement and evolving reimbursement landscapes. The company's strategic shift away from PancraGEN due to reimbursement issues highlights the critical importance of payer acceptance and regulatory clarity for diagnostic test commercialization. The focus on thyroid cancer diagnostics aligns with a trend towards personalized medicine and risk stratification for better patient management.

Comparison to Industry Standards

• The gross profit margin of 61.9% for Q2 2026 is strong for a diagnostic services company, though it is important to consider the specific nature of their esoteric tests.
• The shift in revenue from a broader test portfolio (including PancraGEN) to a more focused one on thyroid diagnostics may impact comparability with diversified diagnostic companies.
• The company's reliance on Medicare and commercial payers is standard in the industry, but the loss of a specific Medicare coverage decision for PancraGEN underscores the vulnerability to reimbursement changes.
• The development timeline for new diagnostic tests (12-24 months) is typical, but the requirement for CMS reimbursement approval adds a significant hurdle not present for all industry players.

Legal Proceedings

• There is no pending litigation involving the Company at this time.
• The Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
• The Company could be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy.

Stakeholder Impact

• Shareholders: The delisting from Nasdaq and subsequent trading on OTC markets have adversely affected the common stock. The pursuit of a Nasdaq uplisting and potential capital raises could impact share value and dilution.
• Customers (Physicians, Hospitals, etc.): Continued provision of specialized diagnostic tests for cancer risk assessment, with a focus on thyroid cancer.
• Payers (Medicare, Commercial Insurers): The company's revenue is heavily dependent on reimbursement rates and coverage decisions, as demonstrated by the PancraGEN issue.
• Employees: The company has undergone restructuring, and future growth and stability will impact employment.

Next Steps

• Continue to focus efforts on molecular diagnostic tests for thyroid cancer, ThyGeNEXT and ThyraMIRv2.
• Develop a new molecular diagnostic test for assessing the risk of pancreatic cyst progression to cancer.
• Obtain a positive determination of reimbursement from CMS for the new pancreatic test.
• Seek an uplisting of its Common Stock to Nasdaq.
• Continue to explore various strategic alternatives and financing options for additional liquidity.

Key Dates

Recommendation

The company shows signs of operational stabilization and improved margins post-PancraGEN, but significant risks remain regarding future capital raises, Nasdaq uplisting, and the successful development and reimbursement of new products. The current cash position is adequate for the near term, but long-term growth and sustainability are contingent on external financing and market acceptance.

Keywords

molecular diagnostic testing, pathology services, cancer risk, thyroid cancer, pancreatic cancer, ThyGeNEXT, ThyraMIRv2, PancraGEN